<SEC-DOCUMENT>0001628280-22-004080.txt : 20220228
<SEC-HEADER>0001628280-22-004080.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228060811
ACCESSION NUMBER:		0001628280-22-004080
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220228
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		22683765

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>auph-20220228.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:eddd6663-a7f1-4ee4-9656-dda1c86ff249,g:d6e820bd-d475-4552-a46f-24fcb98ffba9,d:30d4e5741727467f8960704300b7b46d--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>auph-20220228</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF80L2ZyYWc6YThiMDZmZmVkZjE0NGE2M2EzZTJiZDgzMDViM2Y5NWEvdGFibGU6NzY1YTc1YzFkZGYwNGNhMDg5MWU2OTQ0ZDE0YTg3NTMvdGFibGVyYW5nZTo3NjVhNzVjMWRkZjA0Y2EwODkxZTY5NDRkMTRhODc1M18xLTEtMS0xLTI4MjQ2_30707b73-7131-4f62-b8e7-1b985378fdd9">0001600620</ix:nonNumeric><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF80L2ZyYWc6YThiMDZmZmVkZjE0NGE2M2EzZTJiZDgzMDViM2Y5NWEvdGFibGU6NzY1YTc1YzFkZGYwNGNhMDg5MWU2OTQ0ZDE0YTg3NTMvdGFibGVyYW5nZTo3NjVhNzVjMWRkZjA0Y2EwODkxZTY5NDRkMTRhODc1M18yLTEtMS0xLTI4MjQ2_715dc451-941c-4e74-96ca-4399ef33dc39">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="auph-20220228.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i30d4e5741727467f8960704300b7b46d_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM0_1ad4bca4-0eb7-4f30-be46-94ce3b44ac5b">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8yMjU_4338a611-a669-4a31-ba22-73de4c63aa51">February 28, 2022</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjI5_bc53e21f-7f6d-43a2-bd64-b95394891ff9">Aurinia Pharmaceuticals Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6NjBjYzRlNDQ1NjZjNDQ4NWJlNDVmNDQ2YzMwNWU5MWIvdGFibGVyYW5nZTo2MGNjNGU0NDU2NmM0NDg1YmU0NWY0NDZjMzA1ZTkxYl8wLTAtMS0xLTI4MjQ2_7e460a95-98f9-42cb-8f6f-b5068285b89e">Canada</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6NjBjYzRlNDQ1NjZjNDQ4NWJlNDVmNDQ2YzMwNWU5MWIvdGFibGVyYW5nZTo2MGNjNGU0NDU2NmM0NDg1YmU0NWY0NDZjMzA1ZTkxYl8wLTItMS0xLTI4MjQ2_8a5ab976-a70d-4427-974f-8f307c1a261d">001-36421</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6NjBjYzRlNDQ1NjZjNDQ4NWJlNDVmNDQ2YzMwNWU5MWIvdGFibGVyYW5nZTo2MGNjNGU0NDU2NmM0NDg1YmU0NWY0NDZjMzA1ZTkxYl8wLTQtMS0xLTI4MjQ2_9f8656cb-c581-409a-a63f-9f2df76e8533">46-4129078</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Commission File No.)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMw_a0649ff8-78a8-446b-92d7-55ce39205a23">#1203-4464 Markham Street</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMx_3ac08eeb-02ce-43e3-9947-0eaec8dfccda">Victoria</ix:nonNumeric>, <ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM1_2d36351d-31e9-4b48-9551-20cb9aab6c20">British Columbia</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM2_e6178c91-07e0-4bd9-b948-f6cd292b826e">V8Z 7X8</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">(<ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMy_3efc4cbe-f83c-469a-b44d-2b95e8cc29c5">250</ix:nonNumeric>) <ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM3_bf66638d-89ec-4930-94d1-06cef2105d75">708-4272</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">(Address and telephone number of registrant's principal executive offices)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6MTFmMWE3NzYwZmU1NDE0N2I2ZjliOGQ0YWNlOWFjZGIvdGFibGVyYW5nZToxMWYxYTc3NjBmZTU0MTQ3YjZmOWI4ZDRhY2U5YWNkYl8wLTAtMS0xLTI4MjQ2_d6bf28af-c0cf-4f89-897e-faa8c91413b4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6ZDljYTQ3MDgyOTQ3NDIxY2JmM2NmODUyNjkzYTMyMzgvdGFibGVyYW5nZTpkOWNhNDcwODI5NDc0MjFjYmYzY2Y4NTI2OTNhMzIzOF8wLTAtMS0xLTI4MjQ2_1b691895-8919-4405-8559-4670000b15aa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6ZjQxYTExYzljNzEyNDcwMDllZGE3ZDBkN2MwNjY2Y2MvdGFibGVyYW5nZTpmNDFhMTFjOWM3MTI0NzAwOWVkYTdkMGQ3YzA2NjZjY18wLTAtMS0xLTI4MjQ2_3a35224e-ccd7-4e58-94d4-be5e1b5bce10">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6MmZkZjQzNmExNDhjNGU4MTljNWMxMjcxNWVmOGMzOTAvdGFibGVyYW5nZToyZmRmNDM2YTE0OGM0ZTgxOWM1YzEyNzE1ZWY4YzM5MF8wLTAtMS0xLTI4MjQ2_1724eb00-897e-4b78-8390-ee1ba7bdc08c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of Each Exchange on which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6M2I2ZjRlMjIyY2E0NDBjZmEzNTU0M2UyMGJjMzQyY2MvdGFibGVyYW5nZTozYjZmNGUyMjJjYTQ0MGNmYTM1NTQzZTIwYmMzNDJjY18xLTAtMS0xLTI4MjQ2_9e0ac1d2-13ee-4df6-9bb2-6d8c630d743e">Common Shares, without par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6M2I2ZjRlMjIyY2E0NDBjZmEzNTU0M2UyMGJjMzQyY2MvdGFibGVyYW5nZTozYjZmNGUyMjJjYTQ0MGNmYTM1NTQzZTIwYmMzNDJjY18xLTItMS0xLTI4MjQ2_202bfa98-47e8-4e91-a186-8baa2b3d9835">AUPH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6M2I2ZjRlMjIyY2E0NDBjZmEzNTU0M2UyMGJjMzQyY2MvdGFibGVyYW5nZTozYjZmNGUyMjJjYTQ0MGNmYTM1NTQzZTIwYmMzNDJjY18xLTQtMS0xLTI4MjQ2_473fb2d4-03bd-4f96-973a-2e5e8449c2de">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMz_9d3498bd-1a9c-42ee-bf68-027d8bbf0d2f">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#160;&#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i30d4e5741727467f8960704300b7b46d_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, Aurinia Pharmaceuticals Inc. ("Aurinia") issued a press release announcing its financial results for the quarter and year ended December&#160;31, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto, that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(d) Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_q42021pressrele.htm">Press release dated February 28, 2022, Announcing Fourth Quarter and Full Year 2021 Financial Results and Company Updates</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:1pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i30d4e5741727467f8960704300b7b46d_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">SIGNATURES</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: February&#160;28, 2022</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.055%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AURINIA PHARMACEUTICALS INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_q42021pressrele.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i63503f235ea44fc69d9e8d02695cc60d_1"></div><div style="min-height:115.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr><tr style="height:78pt"><td colspan="9" style="padding:0 1pt"><div><img alt="aurinalogo.jpg" src="aurinalogo.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:277px"></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND COMPANY UPDATES</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">$23.4 million in net revenue for the fourth quarter 2021 (60% increase from third quarter) and $45.6 million in net revenue for full year 2021</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">2021 readout of strong results from AURORA 2 continuation study fuels momentum for year two of launch</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Cash and cash equivalents, and investments of $466.1 million as of December 31, 2021</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Company projects a net revenue guidance range of $115-$135 million from sales of LUPKYNIS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">TM</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> (voclosporin) for 2022 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Conference call to be hosted today at 8&#58;30 a.m. ET</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VICTORIA, British Columbia &#8211; February 28, 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Aurinia Pharmaceuticals Inc. (NASDAQ&#58; AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and year ended December&#160;31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia achieved $23.4 million and $45.6 million</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the quarter and full year ended December&#160;31, 2021, respectively. These results align with the previously stated annual revenue estimate in the range of $40 to $50 million for 2021. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;In the fourth quarter 2021, we performed well against our commercial launch objectives, doubling our total revenue from the previous three quarters with increases in LUPKYNIS patient start forms and improved conversion rates and payor coverage,&#8221; said Peter Greenleaf, President and Chief Executive Officer of Aurinia. &#8220;Despite unpredictable COVID realities, varying by geographic region, as well as the typical challenges we would expect to manage in the first year of a product launch, we are very pleased with the progress we have made to ensure awareness, adoption, and access to LUPKYNIS.&#8221; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#454545;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The positive results from the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AURORA 2 two-year continuation study, announced in December 2021,</font><font style="color:#454545;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will fuel our momentum and differentiate LUPKYNIS going forward as we have the first and only FDA-approved medicine for LN with three years of pivotal trial results, including long-term safety data. Outside of the U.S., we continue to work closely with our partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) to secure regulatory approval of voclosporin in the EU and expand global access to this important treatment,&#8221; added Mr. Greenleaf. &#8220;With a healthy balance sheet, including approximately </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$466.1 million</font><font style="color:#454545;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of cash, cash equivalents and investments on hand as of year end, strong commercial, research and development programs, and talented, passionate employees, we are poised for continued growth and success as we work to change the course of lupus nephritis and other autoimmune diseases.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fourth Quarter 2021 Highlights &#38; Upcoming Milestones&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aurinia added 477 patient start forms (PSFs) in Q4 2021, a 17% increase from Q3 2021, with a total of 1,572 PSFs received during 2021.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PSF conversion rates continue to increase with more than 70% of PSFs converted to patients on therapy. Time to convert continues to decrease since launch&#58; 30- and 60-day conversion rates have improved each month.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Since January 2021 (launch of LUPKYNIS), the Company has secured a total of 1,773 PSFs to date.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aurinia now has confirmed payor coverage in plans covering more than 90% of total lives in the United States.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2021, the Company presented top-line data from the AURORA 2 two-year continuation study demonstrating a favorable risk&#47;benefit profile for voclosporin over a three-year period, with safety comparable to AURORA 1, and sustained efficacy. Additional data from this study is expected to be published and presented in peer-reviewed journals and&#47;or medical meetings throughout 2022.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory review of the European Medicines Agency (EMA) marketing authorization application (MAA) remains on track with a Committee for Medicinal Products for Human Use (CHMP) opinion expected in the second half of 2022 followed by a European Commission (EC) approval decision expected in the second half of 2022. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Further stabilized balance sheet through the utilization of an at the market offering (ATM), raising net proceeds of $196.7 million through December 31, 2021, at an average price of $19.91 and at an average discount of 2.63%. The Company has terminated the ATM sales agreement with no further sales to occur under the ATM.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Liquidity at December&#160;31, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Aurinia had cash and cash equivalents and investments of $466.1 million compared to $422.7 million at December&#160;31, 2020. The increase was primarily due to the receipt of net proceeds from the Company&#8217;s ATM offering, cash proceeds from the exercise of stock options and warrants and cash receipts from the sale of LUPKYNIS, offset by the commercial infrastructure spend to support the launch of LUPKYNIS. The offset also includes payments for inventory, an upfront payment made as part of a collaborative agreement with Lonza to build a dedicated manufacturing capability (or monoplant) and an upfront license payment related to its recently acquired developmental programs (AUR200 and AUR300).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $157.7&#160;million for the year ended December&#160;31, 2021 compared to $69.9 million for the year ended December&#160;31, 2020. The increase was primarily due to the commercial infrastructure spend to support the launch of LUPKYNIS, payments for inventory, an upfront payment made as part of a collaborative agreement with Lonza to build the monoplant, payments to advance clinical programs and one-time payments to a related party upon achievement of specific milestones partially offset by cash receipts from sales of LUPKYNIS. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has sufficient financial resources to fund its current plans, which include funding commercial activities, including FDA related post approval commitments, manufacturing and packaging of commercial drug supply, funding its supporting commercial infrastructure, conducting planned research and development (R&#38;D) programs, investing in its pipeline, executing on its business development strategy and funding its operating activities for at least the next few years.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Results for the Quarter and Year Ended December&#160;31, 2021</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total net revenue was $23.4 million and $50.0 million for the quarters ended December&#160;31, 2021 and December&#160;31, 2020, respectively. Total net revenue was $45.6 million and $50.1 million for the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. The net revenue for the quarter ended and year ended December 31, 2021, primarily consisted of commercial sales of LUPKYNIS, following FDA approval in January of 2021. Total revenue for the quarter and year ended December 31, 2020, was primarily due to an upfront payment from Otsuka of $50.0 million resulting from entering into its collaboration agreement with Otsuka.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales were $0.5 million and nil for the quarters ended December&#160;31, 2021 and December&#160;31, 2020, respectively. Cost of sales were $1.1 million and nil for the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. In 2020, the Company did not have any drugs approved for commercial sale and the upfront payment from Otsuka did not have cost of sales associated with it. Gross margin for the three and twelve months ended December&#160;31, 2021 was approximately 98%.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&#38;A) expenses were $44.2 million and $38.8 million for the quarters ended December&#160;31, 2021 and December&#160;31, 2020, respectively. For the years ended December&#160;31, 2021 and December&#160;31, 2020, SG&#38;A expenses were $171.4 million and $96.0 million, respectively. The increase for both periods was due to the increase in salaries, incentive pay and employee benefits related to the expansion of the commercial and administrative functions to support the launch and commercialization of LUPKYNIS which ramped up during the third quarter of 2020. Also contributing was an increase in travel, trade shows and sponsorships connected with the sales activity occurring in 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash SG&#38;A share-based compensation expense were $7.2 million and $4.5 million for the quarters ended December&#160;31, 2021 and December&#160;31, 2020, respectively. For the years ended December&#160;31, 2021 and December&#160;31, 2020, non-cash share-based compensation expense were $26.4 million and $13.6 million, respectively.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarters ended December&#160;31, 2021 and December&#160;31, 2020, research and development (R&#38;D) expenses were $11.1 million and $13.2 million, respectively. The primary driver for the decrease was due to the decrease in salaries, incentive pay and employee benefits due to the allocation of costs related to post approval support of LUPKYNIS to SG&#38;A.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and December&#160;31, 2020, R&#38;D expenses were $51.1 million and $50.3 million, respectively. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary drivers for the increase were due to the upfront license and accrued milestone expenses related to its recently acquired developmental programs, AUR200 and AUR300, and higher clinical research organization expenses related to its new clinical programs offset by a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in voclosporin development costs following the approval of LUPKYNIS.</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash R&#38;D share-based compensation expense were $1.2 million and $0.6 million for quarters ended December&#160;31, 2021 and December&#160;31, 2020, respectively. For the years ended December&#160;31, 2021 and December&#160;31, 2020, non-cash share-based compensation expense were $4.4 million and $3.7 million, respectively.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarter ended December&#160;31, 2021, Aurinia recorded a net loss of $33.3 million or $0.25 net loss per common share, as compared to a net loss of $8.1 million or $0.06 net loss per common share for the quarter ended December&#160;31, 2020. For the year ended December&#160;31, 2021, Aurinia recorded a net loss of $181.0 million or $1.40 net loss per common share as compared to a net loss of $102.7 million or $0.87 net loss per common share for the previous period.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release is intended to be read in conjunction with the Company&#8217;s consolidated financial statements and Management's Discussion and Analysis for the year ended December&#160;31, 2021 in the Company&#8217;s Annual Report on Form 10-K, which will be accessible on Aurinia's website at www.auriniapharma.com, on SEDAR at www.sedar.com or on EDGAR at www.sec.gov&#47;edgar.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call Details</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia will host a conference call and webcast to discuss the quarter and year ended December&#160;31, 2021 financial results today, Monday, February 28, 2022 at 8&#58;30 a.m. ET. The audio webcast can be accessed under &#34;News&#47;Events&#8221; through the &#8220;Investors&#8221; section of the Aurinia corporate website at www.auriniapharma.com. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. &#38; Canada). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Lupus Nephritis</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LN is a serious progression of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S. and approximately one out of three of these individuals have already developed LN at the time of SLE diagnosis. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in kidney failure. Black and Asian individuals with SLE are four times more likely to develop LN and individuals with Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to Caucasian individuals.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Aurinia</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company has introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active LN. The Company&#8217;s head office is in Victoria, British Columbia, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="text-align:center;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements or information with respect to&#58; Aurinia&#8217;s estimates as to annual net revenue from sales of LUPKYNIS in the range of $115-$135 million in 2022&#59; Aurinia&#8217;s estimates as to the number of patients with SLE in the U.S. and the proportion of those persons who will develop LN&#59; Aurinia being confident that it is poised for growth and success&#59; Aurinia&#8217;s belief that it has sufficient financial resources to fund its current plans for at least the next few years&#59; and the expected timing for the EMA CHMP opinion and EC decision relating to the EMA MAA. It is possible that such results or conclusions may change. Words such as &#8220;anticipate&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;target&#8221;, &#8220;plan&#8221;, &#8220;goals&#8221;, &#8220;objectives&#8221;, &#8220;may&#8221; and other similar words and expressions, identify forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about&#58; the accuracy of reported data from third party studies and reports&#59; the number, and timing of receipt, of PSFs and their rate of conversion into patients on therapy&#59; that Aurinia&#8217;s intellectual property rights are valid and do not infringe the intellectual property rights of third parties&#59; Aurinia&#8217;s assumptions relating to the capital required to fund operations&#59; the assumption that Aurinia&#8217;s current good relationships with its suppliers, service providers and other third parties will be maintained&#59; assumptions relating to the burn rate of Aurinia&#8217;s cash for operations&#59; the relationship between COVID vaccinations and patient treatment&#59; assumptions related to timing of interactions with regulatory bodies&#59; and that Aurinia&#8217;s third party service providers will comply with their contractual obligations. Even though the management of Aurinia believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Aurinia to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following&#58; Aurinia&#8217;s actual future financial and operational results may differ from its expectations&#59; difficulties Aurinia may experience in completing the commercialization of voclosporin&#59; the market for the LN business may not be as estimated&#59; Aurinia may have to pay unanticipated expenses&#59; Aurinia may not be able to obtain sufficient supply to meet commercial demand for voclosporin in a timely fashion&#59; unknown impact and difficulties imposed by the COVID-19 pandemic on Aurinia&#8217;s business operations including nonclinical, clinical, regulatory and commercial activities&#59; the results from Aurinia&#8217;s clinical studies and from third party studies and reports may not be accurate&#59; Aurinia&#8217;s third party service providers may not, or may not be able to, comply with their obligations under their agreements with Aurinia&#59; regulatory bodies may not grant approvals on conditions acceptable to Aurinia and its business partners, or at all&#59; and Aurinia&#8217;s assets or business activities may be subject to disputes that may result in litigation or other legal claims. Although Aurinia has attempted to identify factors that would cause actual actions, events, or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements, or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond Aurinia&#8217;s control. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking information contained in this press release is qualified by this cautionary statement. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia&#8217;s most recent Annual Report on Form 10-K available by accessing the Canadian Securities Administrators&#8217; System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission&#8217;s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov&#47;edgar, and on Aurinia&#8217;s website at www.auriniapharma.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor&#47;Media Contact&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dana Lynch </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate Communications, Aurinia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">dlynch&#64;auriniapharma.com</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i63503f235ea44fc69d9e8d02695cc60d_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">231,900</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">272,350&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">234,178</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15,414</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19,326</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,927&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,506</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">513,324</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">419,427&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,380&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,838</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">247&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,418</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,786&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intellectual property and other intangible assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,404</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,332&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,383</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,489&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">543,367</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,661&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,947</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,797&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities (of which $6,000 due to related party in 2020)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,640</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,412&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,059</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">788&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">40,646</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,997&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation and other non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15,950</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,680</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,619&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">64,276</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,911&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders&#8217; Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares - no par value, unlimited shares authorized, 141,600 and 126,725 shares issued and outstanding at December 31, 2021 and 2020, respectively</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,177,051</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">944,328&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">59,014</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(852)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(805)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(756,122)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(575,156)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total shareholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">479,091</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">407,750&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">543,367</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,661&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i63503f235ea44fc69d9e8d02695cc60d_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,375</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,488</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and contract revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,030&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,118&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,404</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,030&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,605</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,118&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">481</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,091</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,242</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,438</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,983&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,173&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,327&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">522</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(285)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">574</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,809&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales and operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,082&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226,340</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,408&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32,705)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,052)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(180,735)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,290)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">529</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32,596)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,917)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(180,206)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,774)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">726</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">760</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33,322)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,074)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(180,966)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,680)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.25)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.40)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.87)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding used in computation of basic and diluted loss per share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132,054</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,618&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,369</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,473&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>auph-20220228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eddd6663-a7f1-4ee4-9656-dda1c86ff249,g:d6e820bd-d475-4552-a46f-24fcb98ffba9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:auph="http://www.auriniapharma.com/20220228" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.auriniapharma.com/20220228">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.auriniapharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>auph-20220228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eddd6663-a7f1-4ee4-9656-dda1c86ff249,g:d6e820bd-d475-4552-a46f-24fcb98ffba9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_d3a660cd-7ffd-4a28-8c87-b1e240b5d163_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_38638c36-adb3-4eaf-ae72-677df724d029_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_82bf69ce-034d-4609-b3d8-376e67d49d26_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5d185d98-7ba3-4f8c-a31c-b9832d69f9d5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_cdc5ef82-a66c-47f2-a604-5fd18c4b3135_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5138377d-d52a-4390-a9c1-29e49a721e5d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4ce5ec90-dfcd-45e5-931b-650dfe469e6e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e13dc8ac-8d0d-44e4-bfe5-f20d96eec37d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_365e39f3-0fb8-47f1-a242-85a75536b27e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_71f72adf-7d22-4a98-9dc3-989132db3a2e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9271a2ca-85e2-4a81-b25e-7ee55fbf9773_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_611002e5-4ab0-4a17-a11a-980cbaee1b3a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6d4419a2-c05f-4c29-a668-caa4feb5cb79_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ac4beb65-97aa-4a4f-b4d7-be2775e5226e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0572758c-a30d-48d4-a323-5c34797b25d9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ac158369-fe74-44f4-adb9-d2087aaaf0ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2189ed11-b64b-4912-bdd4-eeee2c0963b3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_431a22f1-c4b9-42c1-af88-cb1484be5370_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f11cb03f-41bf-458e-89eb-1d1a14a30005_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_32d08707-945f-42d7-bebe-63c819edf97f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ccb84210-2bc3-42ef-a040-ba230992fe2c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_006e2e82-f9e3-4cd6-b265-ebb51c42de80_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>auph-20220228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:eddd6663-a7f1-4ee4-9656-dda1c86ff249,g:d6e820bd-d475-4552-a46f-24fcb98ffba9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CoverPage" xlink:type="simple" xlink:href="auph-20220228.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d416b855-03a3-469d-8f87-eb6ed4500665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_DocumentType_d416b855-03a3-469d-8f87-eb6ed4500665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ad68526d-f75f-40b9-b4a3-2f35d420324a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_DocumentPeriodEndDate_ad68526d-f75f-40b9-b4a3-2f35d420324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a7bfce64-ee07-451c-b6c1-3e185666c4dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityRegistrantName_a7bfce64-ee07-451c-b6c1-3e185666c4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7f716b06-dc26-4932-887c-9a3f0f39054d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7f716b06-dc26-4932-887c-9a3f0f39054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_56dec4d2-330f-4e0b-8f52-087aff248963" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityFileNumber_56dec4d2-330f-4e0b-8f52-087aff248963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3bc9b3d7-1c84-4b8c-8a7a-564f546c8e13" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityTaxIdentificationNumber_3bc9b3d7-1c84-4b8c-8a7a-564f546c8e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_93f53f05-ffb6-4ea5-9ba9-cf0285d0dbc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityAddressAddressLine1_93f53f05-ffb6-4ea5-9ba9-cf0285d0dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b733fac2-4707-40fa-96bf-06500c04d0ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityAddressCityOrTown_b733fac2-4707-40fa-96bf-06500c04d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4aba9078-fb9d-457e-9b1a-9cb9e23d9cd2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityAddressStateOrProvince_4aba9078-fb9d-457e-9b1a-9cb9e23d9cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1a9b7e51-1ad5-489b-86c1-ba89e34b1f56" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityAddressPostalZipCode_1a9b7e51-1ad5-489b-86c1-ba89e34b1f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_37a0c9bc-e2df-43aa-9614-151f02f9bbda" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_CityAreaCode_37a0c9bc-e2df-43aa-9614-151f02f9bbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aa70383c-ecbc-4b09-9530-4686fe18cf5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_LocalPhoneNumber_aa70383c-ecbc-4b09-9530-4686fe18cf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cfb42a31-9536-45c9-9824-a63422a72c7d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_WrittenCommunications_cfb42a31-9536-45c9-9824-a63422a72c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c175047b-9a1e-4f5f-b65f-a4dbee854b09" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_SolicitingMaterial_c175047b-9a1e-4f5f-b65f-a4dbee854b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ddf09e57-57ef-43fa-b898-415424197fcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_PreCommencementTenderOffer_ddf09e57-57ef-43fa-b898-415424197fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4375673d-3478-4dd7-9cbe-e6964c6ea9ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4375673d-3478-4dd7-9cbe-e6964c6ea9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_68b7ae80-2716-4f54-a645-204004b5099b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_Security12bTitle_68b7ae80-2716-4f54-a645-204004b5099b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b598f52f-db7a-4380-8717-7cf3a505d1e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_TradingSymbol_b598f52f-db7a-4380-8717-7cf3a505d1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4979639b-f4d9-456c-9386-786ccb5711d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_SecurityExchangeName_4979639b-f4d9-456c-9386-786ccb5711d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c05439c8-786d-4069-be3d-f8bf6f1ae0b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityEmergingGrowthCompany_c05439c8-786d-4069-be3d-f8bf6f1ae0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c81bc04f-1d07-48f0-ae49-271ef40b7d00" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_EntityCentralIndexKey_c81bc04f-1d07-48f0-ae49-271ef40b7d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ded71fef-f49f-4910-996a-e74f5826b80a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44f43b30-f061-4d46-b12c-59cbcc9d9be0" xlink:to="loc_dei_AmendmentFlag_ded71fef-f49f-4910-996a-e74f5826b80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>aurinalogo.jpg
<TEXT>
begin 644 aurinalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9A;&5R:64@
M4F5P;W-A    !9 #  (    4   0J) $  (    4   0O)*1  (    #-3@
M )*2  (    #-3@  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C$Z,#(Z,C @,3(Z-#8Z-3D ,C R,3HP
M,CHR," Q,CHT-CHU.0   %8 80!L &4 <@!I &4 ( !2 &4 < !O ', 80
M /_A"R%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A
M9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(Q+3 R+3(P5#$R.C0V
M.C4Y+C4W-SPO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^/')D9CIL:3Y686QE<FEE(%)E<&]S83PO<F1F.FQI/CPO<F1F
M.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D
M9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_
M>'!A8VME="!E;F0])W<G/S[_VP!#  <%!08%! <&!08(!P<("A$+"@D)"A4/
M$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!#
M 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !G 38# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M65XX^*<_CW1[OP]\/K*XFAD@9[^_ECV+'"!E@,],C@D]N!UXU?V;/^1#O_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140143401402632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aurinia Pharmaceuticals Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4129078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">#1203-4464 Markham Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Victoria<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V8Z 7X8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">708-4272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, without par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AUPH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001600620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>auph-20220228_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="auph-20220228.xsd" xlink:type="simple"/>
    <context id="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF80L2ZyYWc6YThiMDZmZmVkZjE0NGE2M2EzZTJiZDgzMDViM2Y5NWEvdGFibGU6NzY1YTc1YzFkZGYwNGNhMDg5MWU2OTQ0ZDE0YTg3NTMvdGFibGVyYW5nZTo3NjVhNzVjMWRkZjA0Y2EwODkxZTY5NDRkMTRhODc1M18xLTEtMS0xLTI4MjQ2_30707b73-7131-4f62-b8e7-1b985378fdd9">0001600620</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF80L2ZyYWc6YThiMDZmZmVkZjE0NGE2M2EzZTJiZDgzMDViM2Y5NWEvdGFibGU6NzY1YTc1YzFkZGYwNGNhMDg5MWU2OTQ0ZDE0YTg3NTMvdGFibGVyYW5nZTo3NjVhNzVjMWRkZjA0Y2EwODkxZTY5NDRkMTRhODc1M18yLTEtMS0xLTI4MjQ2_715dc451-941c-4e74-96ca-4399ef33dc39">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM0_1ad4bca4-0eb7-4f30-be46-94ce3b44ac5b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8yMjU_4338a611-a669-4a31-ba22-73de4c63aa51">2022-02-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjI5_bc53e21f-7f6d-43a2-bd64-b95394891ff9">Aurinia Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6NjBjYzRlNDQ1NjZjNDQ4NWJlNDVmNDQ2YzMwNWU5MWIvdGFibGVyYW5nZTo2MGNjNGU0NDU2NmM0NDg1YmU0NWY0NDZjMzA1ZTkxYl8wLTAtMS0xLTI4MjQ2_7e460a95-98f9-42cb-8f6f-b5068285b89e">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6NjBjYzRlNDQ1NjZjNDQ4NWJlNDVmNDQ2YzMwNWU5MWIvdGFibGVyYW5nZTo2MGNjNGU0NDU2NmM0NDg1YmU0NWY0NDZjMzA1ZTkxYl8wLTItMS0xLTI4MjQ2_8a5ab976-a70d-4427-974f-8f307c1a261d">001-36421</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6NjBjYzRlNDQ1NjZjNDQ4NWJlNDVmNDQ2YzMwNWU5MWIvdGFibGVyYW5nZTo2MGNjNGU0NDU2NmM0NDg1YmU0NWY0NDZjMzA1ZTkxYl8wLTQtMS0xLTI4MjQ2_9f8656cb-c581-409a-a63f-9f2df76e8533">46-4129078</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMw_a0649ff8-78a8-446b-92d7-55ce39205a23">#1203-4464 Markham Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMx_3ac08eeb-02ce-43e3-9947-0eaec8dfccda">Victoria</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM1_2d36351d-31e9-4b48-9551-20cb9aab6c20">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM2_e6178c91-07e0-4bd9-b948-f6cd292b826e">V8Z 7X8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMy_3efc4cbe-f83c-469a-b44d-2b95e8cc29c5">250</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjM3_bf66638d-89ec-4930-94d1-06cef2105d75">708-4272</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6MTFmMWE3NzYwZmU1NDE0N2I2ZjliOGQ0YWNlOWFjZGIvdGFibGVyYW5nZToxMWYxYTc3NjBmZTU0MTQ3YjZmOWI4ZDRhY2U5YWNkYl8wLTAtMS0xLTI4MjQ2_d6bf28af-c0cf-4f89-897e-faa8c91413b4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6ZDljYTQ3MDgyOTQ3NDIxY2JmM2NmODUyNjkzYTMyMzgvdGFibGVyYW5nZTpkOWNhNDcwODI5NDc0MjFjYmYzY2Y4NTI2OTNhMzIzOF8wLTAtMS0xLTI4MjQ2_1b691895-8919-4405-8559-4670000b15aa">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6ZjQxYTExYzljNzEyNDcwMDllZGE3ZDBkN2MwNjY2Y2MvdGFibGVyYW5nZTpmNDFhMTFjOWM3MTI0NzAwOWVkYTdkMGQ3YzA2NjZjY18wLTAtMS0xLTI4MjQ2_3a35224e-ccd7-4e58-94d4-be5e1b5bce10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6MmZkZjQzNmExNDhjNGU4MTljNWMxMjcxNWVmOGMzOTAvdGFibGVyYW5nZToyZmRmNDM2YTE0OGM0ZTgxOWM1YzEyNzE1ZWY4YzM5MF8wLTAtMS0xLTI4MjQ2_1724eb00-897e-4b78-8390-ee1ba7bdc08c">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6M2I2ZjRlMjIyY2E0NDBjZmEzNTU0M2UyMGJjMzQyY2MvdGFibGVyYW5nZTozYjZmNGUyMjJjYTQ0MGNmYTM1NTQzZTIwYmMzNDJjY18xLTAtMS0xLTI4MjQ2_9e0ac1d2-13ee-4df6-9bb2-6d8c630d743e">Common Shares, without par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6M2I2ZjRlMjIyY2E0NDBjZmEzNTU0M2UyMGJjMzQyY2MvdGFibGVyYW5nZTozYjZmNGUyMjJjYTQ0MGNmYTM1NTQzZTIwYmMzNDJjY18xLTItMS0xLTI4MjQ2_202bfa98-47e8-4e91-a186-8baa2b3d9835">AUPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGFibGU6M2I2ZjRlMjIyY2E0NDBjZmEzNTU0M2UyMGJjMzQyY2MvdGFibGVyYW5nZTozYjZmNGUyMjJjYTQ0MGNmYTM1NTQzZTIwYmMzNDJjY18xLTQtMS0xLTI4MjQ2_473fb2d4-03bd-4f96-973a-2e5e8449c2de">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwZDRlNTc0MTcyNzQ2N2Y4OTYwNzA0MzAwYjdiNDZkL3NlYzozMGQ0ZTU3NDE3Mjc0NjdmODk2MDcwNDMwMGI3YjQ2ZF8xL2ZyYWc6MjVkYjg4MzQ2ZmE1NDI4NGJmMGJiOWViMzk4ZjQ5ZWYvdGV4dHJlZ2lvbjoyNWRiODgzNDZmYTU0Mjg0YmYwYmI5ZWIzOThmNDllZl8xMjMz_9d3498bd-1a9c-42ee-bf68-027d8bbf0d2f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V
M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= 9.
MMO8(72A]95,. 46=W=3%<]0!;\K!XVBLA H#E&^J%977DHHM)]W1ZTSO'R:/
M6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ !3%<5"0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ !3%<5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  %,5Q41'"#F.X    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    (  4Q7%09117U-P$  "<"   /
M  "  4$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  %,5Q4)!Z;HJT
M  #X 0  &@              @ &E$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  %,5Q499!YDAD!  #/ P  $P
M@ &*$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #4$P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="auph-20220228.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="auph-20220228.htm">auph-20220228.htm</File>
    <File>auph-20220228.xsd</File>
    <File>auph-20220228_lab.xml</File>
    <File>auph-20220228_pre.xml</File>
    <File>exhibit991_q42021pressrele.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "auph-20220228.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "auph-20220228.htm"
     ]
    },
    "labelLink": {
     "local": [
      "auph-20220228_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "auph-20220228_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "auph-20220228.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "auph",
   "nsuri": "http://www.auriniapharma.com/20220228",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220228.htm",
      "contextRef": "i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.auriniapharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220228.htm",
      "contextRef": "i3d8f0fdcefe84de982f83e6dd83fa0f4_D20220228-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-22-004080-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-004080-xbrl.zip
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M2U,LU;0DW[<*^P< ?8, H\]=#"/4HR/._1)4&WC%C97LM2#A3G6" ;B9+C
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MV-$UP!U& +@LH/@#C/7.N>0[MX(\_1RTX=5I]0&Z=>/T+KKOJF"T4\B#"^^
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M9])I.D:U\<#H, 8FW,%\N82CQ?[-XI%X9WC@:._NA^ZE>US_:.__4$L#!!0
M   (  4Q7%3KUFKDXBL  $C3 0 >    97AH:6)I=#DY,5]Q-#(P,C%P<F5S
M<W)E;&4N:'1M[7UI5]M(UO#W]U?H26>FR7EE(\D[I/L<-Y )[T-(&LCTZ4]S
MRE+9KHXLN;5 /+_^O?=6:?$B8PC8,JCG3  MI:J[;W7K_?^<?CZY^?/+F3:.
M)J[VY>MO%^<GVIO:X>$?C9/#P].;4^WCS:<+K5DW3.TF8%XH(N%[S#T\/+M\
MH[T91]'TZ/#P[NZN?M>H^\'H\.;J$(=J'KJ^'_*Z$SEO?GV/5^!?SIQ?_\_[
M_ZG5M%/?CB?<BS0[X"SBCA:'PAMI?S@\_*;5:NJI$W\Z"\1H'&F685G:'W[P
M3=PR>3\2D<M_3<9Y?RC_?G]('WD_\)W9K^\=<:L)YY<WHMUH&8VAU6AQUFP.
M[7;/Z?&N8UCM7LNVVX;S'Q,F>0B/RW?":.;R7]Y,A%<;<_S^D6FVZM8T.KX3
M3C0^,@WC'V_F'HWX]ZC&7#'RCFC"<'?H>Q%,)("!Y:_I^+^^C]C Y<F[ S]P
M>%"S?==ETY ?);\<.R*<NFQV)#Q7>+Q&+QU/6#"">0W\*/(G1RV8TRT/(F$S
M5WV?IB)O9].M&W+*$4PG<I(OJ]MUNG48.<OW&E;=:C0*;QMUL_#>KH9M;C3L
M(4%"0@, 'DZ9]\N;QIODA2ES'"#((T,SIU%NO*=YU)I^QX>/%ZEF$942BXJ6
MDD%@7#\X^LF@_X[Q3FW()L*='?U\(R8\U"[YG7;E3YCWLQX"P]9"'HBA?# 4
M_^5 #O!I^O-.$G<'QB$*2XB=:.7L^U@,1*3U>G4S)>$<Z)+YJ)<Z75I]?N&]
M0A@1$XC)2&-N],L;%@<"1(H_\NM_34?P4F"ON#CWM1Z \#&L8'4ZT^\IKV?+
M.23F2J\O2H(<HFR0-CQ8R]_WO?5TF&S>ATFS!9CL?[TZOSSO:U=G7SY?W5QK
M'SY_O;KYJ/W^M7]U<W:E]2]/M0]?+RZT/\_Z5RAI3>W#^67_\N2\?P'O7'^]
M@'?PH9//G[[T+__4OGXY[=^<7:^0:V6 B97 A$8\$A%\S9Z#4G,EE-Y:C7I3
M@T^YH. TX6D>C[2 WW(OYMK0#[1HC#_C(!IK?\<L@+E+8!VTC7_ \ZC)0G@B
M\"?PJ B<Y*EW&O,<[6VS56^O&WX8NZXVXTR.^H* :P%P"5  (,>/(\T?PH0"
M'_1]P,/8C4()-"#3SU=]S0(!XD7"BQE:&O!D[,P .-P-M8F/NCZ>$+P(5-&=
MC\.Y+/;L\8/ALJ_0U)(YYZ<S8/:W4>#'GE-3,QO2?\>[F^<)"\=$_#;^PO^.
MP7IS 92A3E>%=\O#"%$:(A+?-MOMNIFR"*.+I]SFDP&P6L/45S/&\R*YC%#U
M)Z!>9]HT\/_B-L".S<F242P<YME< VM]Q FP(.!J;\U&*X4M\5L(N" 87WS]
M\K]_7IY?;Y>J.O7NHP!P//6E$W(4<!=DQ"T_COSI4:U)!OJB!04B&0=X\^O-
MISUA&NW@UK==/YSZ8 "](U%'WL^KD6XGOC?D 4<2!D2Z6N1K ZZ-_1#]Q,AW
MV$QCD=;]YT^M[G'#T%A]4M?.;@H7JJQ$I!&:4F[A?\5A)(:S[1O8%AK8_SX_
MN?E\==[7M=\"(&B0D">^&T\&@FG__*EKF>:Q]H$/ C B9IK5U>>IX'DGO(08
MFG!-ZZ-1#O/[,F;!A-D\)EX+M7//KFL'E_WKT_[OA!=0YE\^OM,.DA>4^:1$
MUSN%1A&&,>!4H 4 QKYG"^9F-L%JDPL5!ZE^[CGP;J(?_OF3V3:.$R51U_H3
M8&I4-+$'4B[4PBFWQ5# &SX,&MR)D(,2"KC&OT_ABR%.P].^UJ_KFH/^=Q#6
MGYRBK";^[QD1E$";V6,!V@",SCF;=LD,74-,3S'7S?F>9K^.MI\== FUY<DL
ML\C7T9J.% O4A9K(G=6UFS$'-R"A8B(+[4X !>/P0&NWPH]#=P8+I, 7\\#2
M=5/M#0:1F, -I$9\(5/B30,EX=N6D6EQJ1J VO>/5%'"6<;QN5?D5NG:'8"+
M![#("8#IC@,NV(@)+P0'(@[ 29A,>$ 20UK_FC_X2V(!N![\C(&+$45\-/*C
M'(25@Y;A OX(>(KY4"(K\>="1$1B(&E3L#<X 0N>1?A/0FG)3L 80X8#UP4L
MD!"Q$P 6Y=TIF_DX8;C#1ERGI8-P#YEPM"\<%_POF #(*3;4M2] .<+!C^"K
M)\#(0^WL.[=C7)GV>3@4-KP !*&8O:XI4)X"%0H@G-B#A3G"EC'&D\__/C]%
MS\L%%8.0N05U@H 9S+01]T<!FXZ%#0^,8,XZ&MT2TB&!*)I-4<!K]A@4,0=*
MQ-O:G1^[#@I. #?2)! #K"NAV*$( $7$-C!+AF:J$\.#$DN$5I2[  PP85V$
ML9/G#Y@2RFMX:LQ@P1/F</P&]\(8WF)W\*X'#\!4'7\:R4D#H)AMXVOP9(*L
M>@+G,EL&JYGC X8#1(B03P("EIY7H* Y$52W J-JJZU_9?>3S+C?]$>Q!6-*
M:0._# @MY(6%\83@'"*1L("^B%,!FF<V.?-$8S6SA\_C'3L. B3@ 0;U$2O<
MNQ7@[T\2J@XXZESR^YB7A4Y@J(D/2([&<-5LD;RS# JNS$=+5BX!)<(4J -M
MQ$7HF<7*O!#I&YO/:VFEV<+_/;\@O4'F(<?HEL^'51 C:S1K@_Y[3J,D">M$
M=WZ-$+(<WT$>]L!@LZ49ECK]I C63/[9H0N2":0A1I](DZ0!**1B1PS)3XD$
MZNN4#$<^<@CH!A!5CA2H4I1EPA'?]CVP 3Z<]FMLJG3'!*4VS(#T^L5E(A11
M-R'8B-BGXI:4613D3&4=6<B-B3-=WQO50*4@@PQY--,<%H&.^!Q'J%5P")P&
MVKDDB14J2,3>^<$W#3U/,&/DQW')P%*1!ZCX'(7QMT7+'^01C',1.6#]RP?0
MM-="4%<!DN$H!@_=!T$O%PDOP 1R[FVB,\Z^$DQ I>"/D>L/X-%,I$<HFT#>
M^$'$@ 8BS!DB(E)5RARTSSX%]4R3IGKQ#UP)T\:@ J/Q#"2;2_(Q'',>Y2%'
M4_Q.QA>L?\O!@LVH<3Y"ME.^ #QB4$]?"NTM1_8\('_/4?&\Q)S6DQ!P9L>1
M(0VW;1DS=$#:N_Z4E :9!6RBXH81?8G#&%-03YB.!O[CDZGKSSB:.,K"F/H"
ME=C03R4._ 7XNXOD!\)8$AA31@U0/] :F#JH TF/ ?U+M>3&4[ 3/3X=DZ<N
M&1C]2(W%D2\FDQC8UH'/H<68&!Z[4CE/08:%KMOJ4,8':;__GD^+?(3[+CX3
M B<VNL?:URG@&CGMDP#5'?E@&E"LX*GAI)*--9</HZ-&>Z5A)R\)#PWMHYHI
M<Y>[,/6(5MK'NU/0QW/@,IOU%L(BC2208&UV.BM=GX,OUQ_"=RC$?V\JIXUI
M9F<Q&_9[(_'HI"B6_ABPE:FW.I:&@P#KVUR@%G3PRZ-[C+:G1/&S&T E13&
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MQVSYGGQ5]NBY.B>(&HX^5EJ_%C.C0%KW](;5WB-I71FBVS9$&WK/ZE1VZ%:
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M,#(R,#(R."YH=&U02P$"% ,4    "  %,5Q4^ZSYUGH"  "6!P  $0
M        @ $M%@  875P:"TR,#(R,#(R."YX<V102P$"% ,4    "  %,5Q4
MB['W$#D*  "B70  %0              @ '6&   875P:"TR,#(R,#(R.%]L
M86(N>&UL4$L! A0#%     @ !3%<5#L0%_>U!@  ?#$  !4
M ( !0B,  &%U<&@M,C R,C R,CA?<')E+GAM;%!+ 0(4 Q0    (  4Q7%3K
MUFKDXBL  $C3 0 >              "  2HJ  !E>&AI8FET.3DQ7W$T,C R
D,7!R97-S<F5L92YH=&U02P4&      4 !0!0 0  2%8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
